EORTC 1417-REACTION:依托泊苷联合铂类±帕博利珠单抗一线治疗广泛期小细胞肺癌的II期研究
REACTION是一项多中心、开放标签、随机II期试验,评估在铂类-依托泊苷基础上加用帕博利珠单抗一线治疗化疗敏感的广泛期小细胞肺癌。125例患者随机1:1分配,主要终点为无进展生存期(PFS)。结果显示加用帕博利珠单抗未改善PFS,中位PFS为4.7个月 vs 5.4个月(HR 0.84,80%CI 0.65-1.09,单侧p=0.194)。
要点
- 在化疗敏感ED-SCLC中,帕博利珠单抗联合铂类-依托泊苷未显著改善PFS。
- 帕博利珠单抗组≥3级不良事件发生率为46%,对照组为26%。
- 随机时每7.5ml血循环肿瘤细胞计数与PFS和OS显著相关,与治疗组无关。
核心结论
- 在化疗敏感的广泛期小细胞肺癌患者中,帕博利珠单抗联合铂类-依托泊苷较单纯化疗未改善无进展生存期。
研究设计与样本
- 多中心、开放标签、随机II期试验,纳入125例患者,随机1:1分配至实验组(帕博利珠单抗+4周期铂类-依托泊苷后帕博利珠单抗)或对照组(铂类-依托泊苷),主要终点为PFS。
主要发现
- 中位PFS在实验组为4.7个月(95%CI 4.2-5.6),对照组为5.4个月(95%CI 4.7-5.6),HR(80%CI)=0.84(0.65-1.09),单侧p=0.194。
- 中位OS在实验组为12.3个月(95%CI 8.9-14.8),对照组为10.4个月(95%CI 8.2-12.2),HR(80%CI)=0.73(0.54-1.0),单侧p=0.097。
- 缓解率实验组为67%,对照组为56%,总缓解率61%。
- ≥3级不良事件发生率实验组为46%,对照组为26%。
- 随机时每7.5ml血循环肿瘤细胞计数与PFS和OS显著相关, regardless of treatment arms.
临床怎么用
- 对于化疗敏感的广泛期小细胞肺癌患者,不推荐在铂类-依托泊苷基础上常规加用帕博利珠单抗。
- 循环肿瘤细胞计数可能有助于预后评估,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-PD-L1 antibodies with platinum-etoposide extend overall survival (OS) of extensive disease Small Cell Lung Cancer (ED-SCLC) patients. We evaluated the benefit of first-line pembrolizumab with platinum-etoposide in chemo-sensitive ED-SCLC. METHODS: REACTION is a multicenter, open-label, randomized phase II trial. Eligible patients (responders after 2 cycles of platinum-etoposide) were randomized 1:1 to experimental arm pembrolizumab in combination with 4 cycles of platinum-etoposide then pembrolizumab vs platinum-etoposide in the control arm. The primary endpoint was progression free survival (PFS). Circulating tumour cells (CTCs) were enumerated and their association with PFS and OS was investigated. RESULTS: Between Feb 7, 2018 and Oct 31, 2019, 125 patients were recruited (61 vs 64 experimental and control arms respectively) with 119 (58 vs 61) eligible and receiving at least one dose of treatment. Baseline characteristics were median age 65 vs 63.5 years, PS 1 (62 vs 60 %), and brain metastases (8 vs 11 %), in the experimental and control arms respectively. Amongst 124 patients who started treatment, 46 (37 %) experienced adverse events grade ≥ 3 for pembrolizumab arm vs 26 % in the control arm. Response rate was 61 % (67 vs 56 %). Median PFS (95 % CI) was 4.7 months (4.2, 5.6) vs 5.4 (4.7, 5.6), HR (80 % CI) = 0.84 (0.65, 1.09) and 1-sided p = 0.194. Median OS (95 % CI) was 12.3 months (8.9, 14.8) vs 10.4 (8.2, 12.2), HR (80 % CI) = 0.73 (0.54, 1.0) and 1-sided p = 0.097. CTC count per 7.5 ml blood at randomization was associated significantly with both PFS and OS regardless of treatment arms. CONCLUSIONS: Pembrolizumab added to platinum-etoposide did not improve PFS over platinum-etoposide alone in chemo-sensitive patients with ED.
引用
- Menis J, Greiller L, Demontrond P, et al. EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. Eur J Cancer. 2025. PMID: 41192233. doi:10.1016/j.ejca.2025.116059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。